Rein Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Rein Therapeutics, Inc. (RNTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 104.30% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-08-14
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-09-30 was 113.60%.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 105.70%, a 11.97% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 94.40%, a 0.00% change year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-03-31 was 94.40%, a 24.21% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 107.10%, a 4.29% decline from fiscal 2024.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 111.90%, a 18.54% increase from fiscal 2023.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 94.40%, a 0.21% increase from fiscal 2022.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 94.20%, a 3.52% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 104.30% 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | 107.10% 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | 107.10% 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | 105.70% 10-Q · filed 2025-08-14 | ||||
| 2024-12-31 | 111.90% 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | 113.60% 10-Q · filed 2024-11-14 | 113.60% 10-Q · filed 2025-11-14 | 104.80% 10-Q · filed 2024-11-14 | ||
| 2024-06-30 | 105.70% 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | 105.70% 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | 94.40% 10-K · filed 2025-04-07 | ||||
| 2023-09-30 | 94.20% 10-Q · filed 2023-10-13 | ||||
| 2023-06-30 | 94.20% 10-Q · filed 2023-08-11 | ||||
| 2023-03-31 | 94.40% 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 94.20% 10-K · filed 2024-04-15 | ||||
| 2022-09-30 | 94.20% 10-Q · filed 2022-11-01 | ||||
| 2022-06-30 | 94.20% 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | 94.40% 10-Q · filed 2023-05-08 | ||||
| 2021-12-31 | 91.00% 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | 91.00% 10-Q · filed 2022-11-01 | ||||
| 2021-06-30 | 91.00% 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | 76.00% 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | 76.00% 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | 76.00% 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | 76.00% 10-Q · filed 2021-08-11 | ||||
| 2020-03-31 | 76.00% 10-Q · filed 2021-05-11 | ||||
| 2019-12-31 | 76.00% 10-K · filed 2021-03-24 | ||||
| 2019-09-30 | 76.00% 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | 76.00% 10-Q · filed 2020-08-05 | ||||
| 2019-03-31 | 76.00% 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | 74.80% 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | 76.00% 10-Q · filed 2019-11-07 | ||||
| 2018-06-30 | 76.00% 10-Q · filed 2019-08-06 | ||||
| 2018-03-31 | 76.00% 10-Q · filed 2019-05-08 | ||||
| 2017-12-31 | 80.40% 10-K · filed 2019-03-29 | ||||
| 2017-09-30 | 80.60% 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | 80.20% 10-Q · filed 2018-08-07 | ||||
| 2017-03-31 | 79.80% 10-Q · filed 2018-05-09 | ||||
| 2016-12-31 | 80.50% 10-K · filed 2018-04-02 | ||||
| 2016-09-30 | 80.50% 10-Q · filed 2017-11-09 | ||||
| 2016-06-30 | 80.50% 10-Q · filed 2017-08-10 | ||||
| 2015-12-31 | 80.50% 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |